Despitethese advantages, its production is constrained by the limitationsof traditional heterologous systems for expressing therapeutic recombinantproteins, leading to high production costs that complicate large-scalemanufacturing.19 Consequently, there isa pressing need for ongoing research aimed at devising more efficacioustherapies and personalized treatment strategies for HER2-positivebreast cancer. The gene discussed is ERBB2; the disease is cancer.